Precision medicine has been gaining ground in recent years with moves by physicians to order more genetic tests to understand how a particular patient’s malady – especially in the field of oncology – may be treated. Payers, including Medicare, are also beginning to cover next-generation sequencing tests. Aside from life science companies, the success of precision medicine also hinges on data analytics companies and software companies.
Chicago-based CancerIQ is one such firm. As we focus on discussing various aspects of precision medicine as part of our virtual INVEST Precision Medicine Conference, Dec.9-11, we thought to spotlight Cancer IQ and its founder and CEO, Feyi Olopade Ayodele. Designed to integrate easily into the clinical workflow, the CancerIQ platforms helps providers identify, evaluate and manage populations based on genetic risk factors while also enabling virtual visits. Click below to learn more.
Tackling Rising Drug Costs and Growing Popularity of GLP-1’s
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Photo: Adam Taylor, Getty Images